Amneal Pharmaceuticals, Inc. (AMRX)

NASDAQ: AMRX · Real-Time Price · USD

19.10

+0.34 (1.81%)

At close: Jul 29, 2026, 4:00 PM EDT

19.40

+0.30 (1.57%)

After-hours: Jul 29, 2026, 7:34 PM EDT

Amneal Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	201.83	310.87	118.42	99.11	35.23	256.74
Cash & Short-Term Investments	201.83	310.87	118.42	99.11	35.23	256.74
Cash Growth	206.87%	162.52%	19.49%	181.34%	-86.28%	-26.04%
Accounts Receivable	850.86	895.14	775.73	613.73	741.79	662.58
Other Receivables	0.51	0.47	0.48	0.96	0.5	1.18
Total Trade Receivables	851.37	895.61	776.22	614.69	742.29	663.76
Inventory	641.62	606.3	612.45	581.38	530.74	489.39
Other Current Assets	103.09	98.4	80.72	82.69	103.57	110.22
Total Current Assets	1,798	1,911	1,588	1,378	1,412	1,520
Net Property, Plant & Equipment	558.76	550.33	523.69	550.14	589.36	639
Other Intangible Assets	534.87	563.5	732.38	890.42	1,096	1,167
Goodwill	593.8	595.47	597.44	598.63	598.85	593.02
Other Long-Term Assets	54.88	57.81	60.13	55.52	103.22	20.61
Total Assets	3,540	3,678	3,501	3,473	3,799	3,940

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	662.98	761.32	735.45	534.66	538.2	525.35
Short-Term Debt	-	-	100	179	60	-
Current Portion of Long-Term Debt	6.2	6.76	224.21	34.13	29.96	30.61
Current Portion of Leases	15.29	14.82	16.04	14.5	14.68	15.42
Other Current Liabilities	43.59	98.74	54.07	84.31	109.96	105.86
Total Current Liabilities	728.05	881.63	1,130	846.6	752.8	677.24
Long-Term Debt	2,566	2,565	2,162	2,427	2,632	2,718
Long-Term Leases	109.44	102.36	91.09	95.45	108.81	111.93
Other Long-Term Liabilities	97.22	123.21	163.33	41.77	97.12	48.52
Total Long-Term Liabilities	2,772	2,791	2,416	2,565	2,838	2,879
Total Liabilities	3,500	3,672	3,546	3,411	3,590	3,556

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	3.19	3.15	3.1	3.07	3.04	3.01
Additional Paid-in Capital	536.3	571.79	560.21	539.24	691.63	658.35
Accumulated Other Comprehensive Income	-112.15	-110.73	-65.51	-32.35	9.94	-24.83
Retained Earnings	-472.75	-535.01	-607.06	-490.18	-406.18	-276.2
Total Common Shareholders' Equity	-45.41	-70.79	-109.27	19.78	298.42	360.34
Minority Interest	85.35	76.76	64.73	41.52	-89.49	23.54
Shareholders' Equity	39.94	5.96	-44.54	61.3	208.93	383.88
Total Liabilities & Equity	3,540	3,678	3,501	3,473	3,799	3,940

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	2,696	2,689	2,593	2,751	2,845	2,876
Net Cash (Debt)	-2,495	-2,378	-2,475	-2,651	-2,810	-2,619
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-7.76	-7.32	-8.01	-15.05	-18.59	-17.26
Book Value	-45.41	-70.79	-109.27	19.78	298.42	360.34
Book Value Per Share	-0.14	-0.22	-0.35	0.11	1.97	2.37
Tangible Book Value	-1,174	-1,230	-1,439	-1,469	-1,397	-1,400
Tangible Book Value Per Share	-3.65	-3.79	-4.66	-8.34	-9.24	-9.22

SEC Filings: 10-K · 10-Q